Olaparib, a cancer drug that blocks a DNA-repair protein called Poly(ADP-ribose) polymerase, reduced tumor size in breast, ovarian and prostate cancer patients who carry BRCA1 and BRCA2 gene mutations, a Phase I study found. Few side effects appeared and those were managed by lowering dosage, researchers said.

Full Story:

Related Summaries